Wedbush assumed coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research note issued to investors on Friday morning, AnalystRatings.com reports. The firm issued a buy rating and a $188.00 price objective on the biotechnology company’s stock.
Several other analysts have also recently issued reports on ASND. Oppenheimer cut their price target on shares of Ascendis Pharma A/S from $219.00 to $208.00 and set an outperform rating on the stock in a report on Wednesday, May 20th. Zacks Investment Research lowered shares of Ascendis Pharma A/S from a buy rating to a hold rating in a research note on Thursday, April 2nd. CSFB lifted their price target on Ascendis Pharma A/S from $149.00 to $154.00 and gave the stock an outperform rating in a research note on Wednesday, May 20th. Credit Suisse Group upped their price objective on Ascendis Pharma A/S from $149.00 to $154.00 and gave the company an outperform rating in a research note on Wednesday, May 20th. Finally, Cantor Fitzgerald boosted their price target on Ascendis Pharma A/S from $185.00 to $201.00 and gave the company an overweight rating in a report on Monday, April 20th. One analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $168.50.
Shares of NASDAQ:ASND opened at $145.21 on Friday. The company has a 50 day moving average of $143.89 and a two-hundred day moving average of $132.65. Ascendis Pharma A/S has a 52-week low of $90.06 and a 52-week high of $158.93. The company has a quick ratio of 13.19, a current ratio of 13.19 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $7.04 billion, a price-to-earnings ratio of -27.24 and a beta of 0.97.
Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Tuesday, May 19th. The biotechnology company reported ($1.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.43) by $0.11. Ascendis Pharma A/S had a negative net margin of 2,231.94% and a negative return on equity of 36.56%. The company had revenue of $2.45 million during the quarter, compared to analysts’ expectations of $2.66 million. On average, equities analysts anticipate that Ascendis Pharma A/S will post -6.24 earnings per share for the current year.
A number of hedge funds have recently made changes to their positions in the stock. Sowell Financial Services LLC acquired a new stake in shares of Ascendis Pharma A/S during the first quarter worth $32,000. Oppenheimer Asset Management Inc. purchased a new position in Ascendis Pharma A/S in the 1st quarter worth about $49,000. Tower Research Capital LLC TRC acquired a new stake in Ascendis Pharma A/S during the 1st quarter worth about $52,000. US Bancorp DE lifted its stake in Ascendis Pharma A/S by 129.2% during the fourth quarter. US Bancorp DE now owns 385 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 217 shares in the last quarter. Finally, Banque Cantonale Vaudoise acquired a new position in shares of Ascendis Pharma A/S in the fourth quarter worth about $87,000. 99.96% of the stock is owned by institutional investors and hedge funds.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.
Further Reading: New Google Finance Tool and Screening Stocks
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.